Targeted therapeutics for pancreatitis

The current targeted therapeutic landscape in pancreatitis is promising, but difficulties lie in trial enrichment as the timing of drug administration is critically dependent on the timeline of disease. Therefore, progress will depend on matching treatment timing to target biology, identifying patients using practical early severity and inflammatory features, and using endpoints that reflect disease modification (organ failure, necrosis, recurrence, fibrosis progression, pancreatic function, and pain trajectories). Trial designs matching these therapeutics to their target biology will help understand the real clinical value of mechanism-based regimens across the AP-RAP-CP continuum.